Stifel Canada upgraded shares of Medexus Pharmaceuticals (TSE:MDP – Free Report) from a moderate buy rating to a strong-buy rating in a research note published on Monday morning, Zacks.com reports.
Separately, Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a strong-buy rating in a report on Wednesday, June 26th.
View Our Latest Stock Analysis on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Down 2.4 %
Medexus Pharmaceuticals (TSE:MDP – Get Free Report) last issued its quarterly earnings results on Tuesday, June 25th. The company reported C$0.04 earnings per share for the quarter, topping analysts’ consensus estimates of C($0.03) by C$0.07. The firm had revenue of C$35.00 million for the quarter, compared to analysts’ expectations of C$34.96 million. Medexus Pharmaceuticals had a return on equity of 3.95% and a net margin of 1.00%. As a group, analysts anticipate that Medexus Pharmaceuticals will post 0.1653386 earnings per share for the current year.
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Recommended Stories
- Five stocks we like better than Medexus Pharmaceuticals
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Find and Profitably Trade Stocks at 52-Week Lows
- Jeff Brown’s Exegesis AI Stock Picks
- Investing in Travel Stocks Benefits
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.